NEPHCURE KIDNEY INTERNATIONAL

Saving Kidneys. Saving Lives.

King of Prussia, PA   |  www.nephcure.org

Mission

NephCure Kidney International is the only nonprofit organization committed exclusively to support research seeking the cause of the potentially debilitating kidney diseases, Nephrotic Syndrome and Focal Segmental Glomerulosclerosis (FSGS), improve treatment and find a cure. NephCure is consists of patients and their families and friends, as well as researchers, physicians and other healthcare professionals joining forces to create awareness and generate funding for research.

Ruling year info

2001

CEO

JOSHUA TARNOFF

Main address

150 S. Warner Road Suite 402

King of Prussia, PA 19406 USA

Show more contact info

Formerly known as

NephCure Foundation

EIN

38-3569922

NTEE code info

Kidney (H44)

Kidney (G44)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

Working with all stakeholders to bring treatments for Nephrotic Syndrome and FSGS to the market.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Research Acceleration

NephCure is working to identify all patients and educate them on clinical trials.

Population(s) Served
Adults

Where we work

Affiliations & memberships

National Organization for Rare Disorders - Member 2018

Videos

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Number of patients positively affected by educating clinicians

This metric is no longer tracked.
Totals By Year
Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

These numbers are estimated by how many clinicians attended our educational offerings and their responses to our surveys.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

NephCure aims to accelerate research into treatments for FSGS and Nephrotic Syndrome.

NephCure is working to identify all NS/FSGS patients and educate them about clinical trials.

NephCure is the only patient advocacy group serving this population. We know the doctors who treat these patients and many of the patients already.

We have partnered with multiple (upwards of 20) pharmaceutical and biotech companies to help recruit for upcoming trials.

Financials

NEPHCURE KIDNEY INTERNATIONAL
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

NEPHCURE KIDNEY INTERNATIONAL

Board of directors
as of 3/3/2021
SOURCE: Self-reported by organization
Board chair

Irv Smokler

No affiliation

Irving Smokler

No Affiliation

Ron Cohen

No Affiliation

Michael Levine

No Affiliation

Andrew Silverman

No Affiliation

Carol Smokler

No Affiliation

Elaine Kamil

No Affiliation

William Smoyer

No Affiliation

David Kershaw

No Affiliation

Kathleen Broderick

No Affiliation

Jim Duquette

No Affiliation

Scott Goldstein

No Affiliation

Sarretta McDonough

No Affiliation

John Roy

No Affiliation

Jennifer Geisser Siegel

No Affiliation

Manu Varma

No Affiliation

Chris Whitney

Mark Winward

Steve Hollomon

Kirk Campbell

Laurel Damashek

Charles Davis

Kevin Mott

Rebecca Oag

Joshua Roy

Christopher Windisch

Martin Zimmerman

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? No
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? No
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No